Thus, to understand the clinical value of S100A8 and A9, it seems more informative to study and compare their variations within different cytological, prognostic, or molecular subtypes of AML rather than in relation to a control group of non-AML patients. Here, IGKV1D-22 is linked to acute myeloid leukemia.